Literature DB >> 2900430

No clinical signs 14 years after HIV-2 transmission via blood transfusion.

G Dufoort, A M Couroucé, R Ancelle-Park, O Bletry.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 2900430     DOI： 10.1016/s0140-6736(88)90154-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Proviral progeny of heterodimeric virions reveal a high crossover rate for human immunodeficiency virus type 2.

Authors:  Sayandip Mukherjee; Hui-Ling Rose Lee; Yacov Ron; Joseph P Dougherty
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

2.  Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology.

Authors:  F Gao; L Yue; D L Robertson; S C Hill; H Hui; R J Biggar; A E Neequaye; T M Whelan; D D Ho; G M Shaw
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

3.  Epidemiology of HIV-2 infection in Spain. The HIV-2 Spanish Study Group.

Authors:  V Soriano; M Gutiérrez; E Caballero; G Cilla; J L Fernández; A Aguilera; C Tuset; F Dronda; A M Martín; E Carballo; I López; J González-Lahoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

4.  Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and kappa B regulatory elements.

Authors:  D M Markovitz; M J Smith; J Hilfinger; M C Hannibal; B Petryniak; G J Nabel
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia.

Authors:  T F Schulz; D Whitby; J G Hoad; T Corrah; H Whittle; R A Weiss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.